Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics.
作者信息
Coller B S
机构信息
Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA.
出版信息
J Clin Invest. 1997 Apr 1;99(7):1467-71. doi: 10.1172/JCI119307.
Abstract
摘要
相似文献
1
Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics.血小板糖蛋白IIb/IIIa拮抗剂：首批抗整合素受体疗法。
J Clin Invest. 1997 Apr 1;99(7):1467-71. doi: 10.1172/JCI119307.
2
Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics.血小板糖蛋白IIb/IIIa拮抗剂：首批抗整合素受体治疗药物。
J Clin Invest. 1997 Dec 1;100(11 Suppl):S57-60.
3
In-vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists and thrombolytics on platelet/fibrin-mediated clot dynamics in human whole blood using thrombelastography.使用血栓弹力图评估不同血小板糖蛋白IIb/IIIa拮抗剂和溶栓剂对人全血中血小板/纤维蛋白介导的血凝块动力学的体外疗效。
Blood Coagul Fibrinolysis. 2007 Jan;18(1):55-60. doi: 10.1097/MBC.0b013e3280116c36.
4
Basic and clinical aspects of platelet integrin alphaIIbbeta3 receptor antagonists in acute coronary syndromes.
Curr Opin Investig Drugs. 2001 Feb;2(2):244-9.
5
Glycoprotein IIb/IIIa receptor antagonists in acute coronary syndromes.
J Invasive Cardiol. 1999 Jun;11 Suppl A:13A-19A.
6
[Inhibitors of the platelet's receptor GPIIb/IIIA. Progress in the treatment of acute myocardial ischemia and future trends].
Minerva Cardioangiol. 2001 Dec;49(6):413-6.
7
8
Glycoprotein IIb/IIIa receptor blockade with coronary stent placement.冠状动脉支架置入术联合糖蛋白IIb/IIIa受体阻滞剂治疗
Semin Interv Cardiol. 1998 Jun;3(2):81-90.
9
A cold start for oral glycoprotein IIb/IIIa antagonists.
Eur Heart J. 2000 Dec;21(24):1992-4. doi: 10.1053/euhj.2000.2458.
10
Antiplatelet efficacy of XV459, a novel nonpeptide platelet GPIIb/IIIa antagonist: comparative platelet binding profiles with c7E3.新型非肽类血小板糖蛋白IIb/IIIa拮抗剂XV459的抗血小板疗效：与c7E3的血小板结合谱比较
J Pharmacol Exp Ther. 1998 Sep;286(3):1277-84.
引用本文的文献
1
Application of Funnel Metadynamics to the Platelet Integrin αIIbβ3 in Complex with an RGD Peptide.Funnel 分子动力学在整合素 αIIbβ3 与 RGD 肽复合物中的应用。
Int J Mol Sci. 2024 Jun 14;25(12):6580. doi: 10.3390/ijms25126580.
2
Molecular mechanisms of catch bonds and their implications for platelet hemostasis.捕获键的分子机制及其对血小板止血的影响。
Biophys Rev. 2023 Sep 26;15(5):1233-1256. doi: 10.1007/s12551-023-01144-8. eCollection 2023 Oct.
3
Influence of integrins on thrombus formation: a road leading to the unravelling of DVT.整合素对血栓形成的影响：解开 DVT 之谜的途径。
Mol Cell Biochem. 2021 Mar;476(3):1489-1504. doi: 10.1007/s11010-020-03961-x. Epub 2021 Jan 4.
4
Direct Fibrinolytic Snake Venom Metalloproteinases Affecting Hemostasis: Structural, Biochemical Features and Therapeutic Potential.直接纤溶蛇毒金属蛋白酶对止血的影响：结构、生化特征和治疗潜力。
Toxins (Basel). 2017 Dec 5;9(12):392. doi: 10.3390/toxins9120392.
5
Abciximab-induced acute profound thrombocytopenia postpercutaneous coronary intervention.经皮冠状动脉介入治疗后阿昔单抗诱发的急性严重血小板减少症
BMJ Case Rep. 2017 Jul 14;2017:bcr-2017-221182. doi: 10.1136/bcr-2017-221182.
6
Abciximab-induced delayed profound thrombocytopaenia.阿昔单抗诱发的迟发性严重血小板减少症。
BMJ Case Rep. 2017 Jun 2;2017:bcr-2017-219379. doi: 10.1136/bcr-2017-219379.
7
A Novel Model of Intravital Platelet Imaging Using CD41-ZsGreen1 Transgenic Rats.一种使用CD41-ZsGreen1转基因大鼠的活体血小板成像新模型。
PLoS One. 2016 Apr 29;11(4):e0154661. doi: 10.1371/journal.pone.0154661. eCollection 2016.
8
Integrin-based therapeutics: biological basis, clinical use and new drugs.基于整合素的疗法：生物学基础、临床应用与新药
Nat Rev Drug Discov. 2016 Mar;15(3):173-83. doi: 10.1038/nrd.2015.10. Epub 2016 Jan 29.
9
[Antiplatelet therapy in acute coronary syndrome. Prehospital phase: nothing, aspirin or what?].[急性冠状动脉综合征的抗血小板治疗。院前阶段：不治疗、使用阿司匹林还是其他？]
Herz. 2014 Nov;39(7):803-7. doi: 10.1007/s00059-014-4157-3.
10
Enhancing the Teaching of Evolution in Public Health.加强公共卫生领域的进化教学。
Evolution (N Y). 2011 Dec;4(4):567-573. doi: 10.1007/s12052-011-0382-x.
本文引用的文献
1
In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time.血小板糖蛋白IIb/IIIa受体拮抗剂c7E3 Fab对活化凝血时间的体外作用。
Circulation. 1997 Feb 4;95(3):614-7. doi: 10.1161/01.cir.95.3.614.
2
3
Adhesion of platelets to surface-bound fibrinogen under flow.流动状态下血小板与表面结合的纤维蛋白原的黏附。
Blood. 1996 Oct 15;88(8):2967-72.
4
5
Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis".小鼠/人嵌合7E3抗体对血小板介导的、组织因子诱导的凝血酶生成的抑制作用。对c7E3 Fab治疗急性血栓形成和“临床再狭窄”效果的潜在影响。
J Clin Invest. 1996 Aug 1;98(3):863-74. doi: 10.1172/JCI118859.
6
Thrombosis and inflammation as multicellular processes: significance of cell-cell interactions.
Thromb Haemost. 1995 Jul;74(1):213-7.
7
Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor.通过黏附于纤维蛋白原或在血管性血友病因子上移位来启动血小板黏附。
Cell. 1996 Jan 26;84(2):289-97. doi: 10.1016/s0092-8674(00)80983-6.
8
Studies of activated GPIIb/IIIa receptors on the luminal surface of adherent platelets. Paradoxical loss of luminal receptors when platelets adhere to high density fibrinogen.对黏附血小板腔表面活化的糖蛋白IIb/IIIa受体的研究。当血小板黏附于高密度纤维蛋白原时，腔表面受体出现矛盾性丢失。
J Clin Invest. 1993 Dec;92(6):2796-806. doi: 10.1172/JCI116899.
9
Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men.
Clin Pharmacol Ther. 1994 Oct;56(4):377-88. doi: 10.1038/clpt.1994.152.
10
Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation.
Circulation. 1994 Nov;90(5):2203-6. doi: 10.1161/01.cir.90.5.2203.
Zotero 插件